ImmunoVaccine Inc. reported earnings results for the year ended December 31, 2010. The company reported net loss and comprehensive loss increased to $6,503,000 for the year ended December 31, 2010, from a loss of $1,664,000 during the nine month period ended December 31, 2009 as a result of a $1,344,000 decrease in revenues and increased research and development expenses primarily related to the Phase I clinical trial of DPX-0907, business development expenses and changes in operating expenses. Revenues from animal health were $76,000, a decrease of $1,344,000 from the nine month period ended December 31, 2009. The company also announced that Dr. Marc Mansour has been appointed as Chief Operating Officer and Chief Science Officer, effective April 20, 2011. In this expanded role, Dr. Mansour will oversee the development of the Company’s operational strategy and will head all clinical research and development activities. Since joining the company, in 2000, Dr. Mansour has advanced the company’s research and led the development of the DepoVa vaccine delivery platform, as well as the Company’s two clinical products, DPX-0907 and DPX-Survivac.

Enagas SA reported earnings results for the first quarter ended March 31, 2011. The company reported net profit for the first three months of 2011 of EUR 86 million, a 4.8% increase on the figure of EUR 82 million to March 31, 2010. EBITDA totaled EUR 205.9 million, 8.6% higher than the previous year's figure of EUR 189.7 million. These results are in line with guidance for the year which calls for net profit growth of 5% and a double-digit increase in EBITDA, in line with the 2010-2014 Strategic Plan. Net debt at March 31, 2011 stood at EUR 3,179 million, compared to EUR 3,021 million in the same period last year. The company invested a total of EUR 130 million in the first quarter of the year and brought into operation projects worth EUR 165 million, in line with its target for the year of EUR 650 million. The Board of Directors agreed to appoint José Riva as President of the Audit and Compliance Committee to replace Martí Parel ada, whose four-year term of office has expired. José Riva Francos is an architect by profession and has been an Independent Director of Enagás since 2002 and a member of the Audit and Compliance Committee since June 2010.

Aer Lingus Group plc announced that its Trevor Jensen has stepped down from his role as chief operating officer after less than 11 months in the role. The company announced that Mr. Jensen was moving by agreement to the position of special adviser to the airline s safety committee. Mr. Jensen will report in this role to non-executive director Francis Hackett, who is chairman of this committee. Mr. Mueller said Mr. Jensen would provide advice on global best practices in aviation-related safety matters.